Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes.

Détails

Ressource 1Télécharger: serval:BIB_F6BBBCACCC3A.P001 (284.33 [Ko])
Etat: Public
Version: de l'auteur
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_F6BBBCACCC3A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes.
Périodique
European Heart Journal
Auteur(s)
Nanchen D., Gencer B., Auer R., Räber L., Stefanini G.G., Klingenberg R., Schmied C.M., Cornuz J., Muller O., Vogt P., Jüni P., Matter C.M., Windecker S., Lüscher T.F., Mach F., Rodondi N.
ISSN
1522-9645 (Electronic)
ISSN-L
0195-668X
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
36
Numéro
36
Pages
2438-2445
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
AIMS: We aimed to assess the prevalence and management of clinical familial hypercholesterolaemia (FH) among patients with acute coronary syndrome (ACS).
METHODS AND RESULTS: We studied 4778 patients with ACS from a multi-centre cohort study in Switzerland. Based on personal and familial history of premature cardiovascular disease and LDL-cholesterol levels, two validated algorithms for diagnosis of clinical FH were used: the Dutch Lipid Clinic Network algorithm to assess possible (score 3-5 points) or probable/definite FH (>5 points), and the Simon Broome Register algorithm to assess possible FH. At the time of hospitalization for ACS, 1.6% had probable/definite FH [95% confidence interval (CI) 1.3-2.0%, n = 78] and 17.8% possible FH (95% CI 16.8-18.9%, n = 852), respectively, according to the Dutch Lipid Clinic algorithm. The Simon Broome algorithm identified 5.4% (95% CI 4.8-6.1%, n = 259) patients with possible FH. Among 1451 young patients with premature ACS, the Dutch Lipid Clinic algorithm identified 70 (4.8%, 95% CI 3.8-6.1%) patients with probable/definite FH, and 684 (47.1%, 95% CI 44.6-49.7%) patients had possible FH. Excluding patients with secondary causes of dyslipidaemia such as alcohol consumption, acute renal failure, or hyperglycaemia did not change prevalence. One year after ACS, among 69 survivors with probable/definite FH and available follow-up information, 64.7% were using high-dose statins, 69.0% had decreased LDL-cholesterol from at least 50, and 4.6% had LDL-cholesterol ≤1.8 mmol/L.
CONCLUSION: A phenotypic diagnosis of possible FH is common in patients hospitalized with ACS, particularly among those with premature ACS. Optimizing long-term lipid treatment of patients with FH after ACS is required.
Mots-clé
Acute Coronary Syndrome/complications, Acute Coronary Syndrome/epidemiology, Analysis of Variance, Atherosclerosis/epidemiology, Atherosclerosis/prevention & control, Cholesterol, LDL/drug effects, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Hyperlipoproteinemia Type II/complications, Hyperlipoproteinemia Type II/drug therapy, Male, Middle Aged, Prevalence, Proprotein Convertases/antagonists & inhibitors, Quality of Health Care, Serine Endopeptidases, Switzerland
Pubmed
Web of science
Open Access
Oui
Création de la notice
27/10/2015 17:32
Dernière modification de la notice
25/09/2019 6:11
Données d'usage